Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Ordinary Shares, par value NIS 0.01 per share
-
Shares outstanding
-
46,239,275
-
Total 13F shares
-
14,080,142
-
Share change
-
+101,940
-
Total reported value
-
$236,818,324
-
Put/Call ratio
-
96%
-
Price per share
-
$16.82
-
Number of holders
-
89
-
Value change
-
+$1,888,037
-
Number of buys
-
35
-
Number of sells
-
27
Institutional Holders of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) as of Q3 2021
As of 30 Sep 2021,
UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) was held by
89 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
14,080,142 shares.
The largest 10 holders included
MENORA MIVTACHIM HOLDINGS LTD., BlackRock Inc., CREDIT SUISSE AG/, RTW INVESTMENTS, LP, GREAT POINT PARTNERS LLC, ZEKE CAPITAL ADVISORS, LLC, Migdal Insurance & Financial Holdings Ltd., Horton Capital Management, LLC, Wildcat Capital Management, LLC, and Clal Insurance Enterprises Holdings Ltd.
This page lists
89
institutional shareholders reporting positions in this security
for the Q3 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.